Dr. Valent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-445-7238
Summary
- Dr. Jason Valent is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in amyloidosis and multiple myeloma.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2002 - 2006
University of Cincinnati College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2002 - 2025
MI State Medical License 2006 - 2013
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- The first case of Teclistamab interference with serum electrophoresis and immunofixation.Kamran Kadkhoda, Beth Faiman, Jason Valent, Samer Albahra, Nicole Boyert
Clinical Chemistry and Laboratory Medicine. 2024-11-13 - 2 citationsOutcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.Danai Dima, Michael Hughes, Mark Orland, Fauzia Ullah, Utkarsh Goel
Amyloid. 2024-09-01 - Disparities in time to treatment with oral antimyeloma medications.Hamlet Gasoyan, Faiz Anwer, Jeffrey D Kovach, Nicholas J Casacchia, Ming Wang
Blood Cancer Journal. 2024-08-23
Abstracts/Posters
- Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple MyelomaJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) PatientsJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Rapid Infusion Daratumumab Is Safe in Patients with AL AmyloidosisJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Ref...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- ASH 2020 Study Preview: Dose Escalation of Cael-101 in AL Amyloidosis PatientsDecember 2020
Press Mentions
Reader Responses: Should a Mostly Asymptomatic Patient with Amyloidosis Receive Systemic Therapy?May 1st, 2021- Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Study Tests Targeted Drugs for Multiple MyelomaApril 1st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
